Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06703749 · ClinicalTrials.gov registry record · NA
HIFEM and Radiofrequency for Muscular System Function Improvement
A NA study of Muscle Weakness and Muscle Damage, sponsored by BTL Industries.
- Active
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 3
- Study locations
NCT06703749: Active NA study of Muscle Weakness and Muscle Damage, sponsored by BTL Industries.
NCT06703749 is a NA study of Muscle Weakness and Muscle Damage that is active but no longer recruiting, run by BTL Industries. The registered enrollment target is 33 participants, below the 74-participant average among 25 other Muscle Weakness trials with a reported enrollment target (55% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06703749, a NA study of Muscle Weakness and Muscle Damage, is active but no longer recruiting, sponsored by BTL Industries.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to investigate the effect of the BTL-899M device on muscular system function in adult subjects seeking treatment for improving their muscular system function in the lower extremities. The main question it aims to answer is: Whether the BTL-899M device is effective for muscular system function improvement 3 months posttreatment compared to the sham group, based on the dynamometer measurement. Researchers will compare a sham group to see if the device is effective. Participants will complete four treatment visits and two follow-up visits. Their strength will be recorded via a dynamometer.
Primary Outcome
The evaluation of the percentual (%) change in muscle strength in the active group by evaluation of dynamometer score 3 months posttreatment compared to the sham group
Conditions Studied
Interventions
- DEVICE Treatment with BTL-899M
- DEVICE Treatment with BTL-899M with intensities below therapeutic threshold
Study Locations (3)
Arizona
- Royal Spine Surgery - Scottsdale
Colorado
- The Longevity Lab - Greenwood Village
Florida
- Saville Spine Institute - Palm Beach Gardens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2025-06 |
| Phase | NA |
What the registry record for NCT06703749 still lists
NCT06703749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 74-participant average among 25 other Muscle Weakness trials with a reported enrollment target (55% lower).
The record links to 3 conditions, with Muscle Weakness appearing as the primary indexed condition, and to 2 interventions - of which Treatment with BTL-899M is the first listed.
NCT06703749 reports a single indexed study location in Arizona, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT06703749 about?
NCT06703749 is a clinical study titled "HIFEM and Radiofrequency for Muscular System Function Improvement". The goal of this clinical trial is to investigate the effect of the BTL-899M device on muscular system function in adult subjects seeking treatment for improving their muscular system function in the lower extremities. The main question it aims to answer is: Whether the BTL-899M device is effective...
What is the current status of trial NCT06703749?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 33 participants. The study started on 2024-04-22. Estimated completion is 2025-06.
What conditions does trial NCT06703749 study?
This clinical trial studies the following conditions: Muscle Weakness, Muscle Damage, Muscle Strength.
What interventions are being tested in trial NCT06703749?
The interventions under investigation include: Treatment with BTL-899M (DEVICE), Treatment with BTL-899M with intensities below therapeutic threshold (DEVICE).
Who is sponsoring clinical trial NCT06703749?
This trial is sponsored by BTL Industries, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06703749 being conducted?
This trial has 3 study locations across Arizona, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle Weakness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06703749's enrollment target sits among peer trials
33 16th of 25 higher than 10 of 25 other Muscle Weakness trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Muscle Weakness trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
FIT Exercise in 30d of ULLS-induced Muscle Disuse
RECRUITING · NA
-
THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation
RECRUITING · NA
-
Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors
RECRUITING · NA
-
Assessing The Effects of Exercise, Protein, and Electric Stimulation On Intensive Care Unit Patients Outcomes
ACTIVE NOT RECRUITING · NA
-
Neuromodulation for Prevention of Intensive Care Unit Acquired Weakness and Post Intensive Care Syndrome
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI